Exploiting a Conjugative Endogenous CRISPR-Cas3 System to Tackle Multidrug-Resistant Klebsiella Pneumoniae.

Ying Zhou,Yang,Xiaobin Li,Dongxing Tian,Wenxiu Ai,Weiwen Wang,Bingjie Wang,Barry N. Kreiswirth,Fangyou Yu,Liang Chen,Xiaofei Jiang
DOI: https://doi.org/10.1016/j.ebiom.2023.104445
IF: 11.205
2023-01-01
EBioMedicine
Abstract:Background Mobile plasmids play a key role in spurring the global dissemination of multidrug-resistant (MDR) K. pneumoniae, while plasmid curing has been recognized as a promising strategy to combat antimicrobial resistance. Here we exploited a K. pneumoniae native CRISPR system to cure the high-risk IncFII plasmids.Methods We examined matched protospacers in 725 completely sequenced IncFII plasmids from K. pneumoniae genomes. Then, we re-engineered a native CRISPR-Cas3 system and deliver the CRISPR-Cas3 system via conjugation. Plasmid killing efficiency and G. mellonella infection model were applied to evaluate the CRISPR-Cas3 immunity in vitro and in vivo.Findings Genomic analysis revealed that most IncFII plasmids could be targeted by the native CRISPR-Cas3 system with multiple matched protospacers, and the targeting regions were highly conserved across different IncFII plasmids. This conjugative endogenous CRISPR-Cas3 system demonstrated high plasmid curing efficiency in vitro (8-log decrease) and in vivo (similar to 100% curing) in a Galleria mellonella infection model, as well as provided immunization against the invasion of IncFII plasmids once the system entering a susceptible bacterial host.Interpretation Overall, our work demonstrated the applicability of using native CRISPR-mediated plasmid curing to re-sensitize drug-resistant K. pneumoniae to multiple antibiotics. This work provided strong support for the idea of utilizing native CRISPR-Cas systems to tackle AMR in K. pneumoniae.
What problem does this paper attempt to address?